Dexcom forecasts 2025 revenue mostly in-line with expectations
Dexcom forecast total annual revenue in line with Wall Street expectations on Monday, on bets of strong demand for its continuous glucose monitors for diabetes patients.
Abbott and DexCom settle glucose monitor patent disputes
Abbott Laboratories said on Monday it and DexCom have reached an agreement to settle all patent disputes between the companies related to continuous glucose monitoring devices.
DexCom (DXCM) Soars 5.6%: Is Further Upside Left in the Stock?
DexCom (DXCM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
1 Reason to Sell DexCom Stock, and 1 Reason to Buy
Shares of the medical-device maker DexCom (DXCM 5.57%) are down by 37% this year. The diabetes-focused healthcare company disappointed investors with its second-quarter results, leading to a massive drop in its stock price overnight.
DXCM Stock Gains on the Launch of Proprietary Generative AI Platform
Dexcom announces the first Generative AI platform in glucose biosensing.
Dexcom's over-the-counter glucose monitor now offers users an AI summary of how sleep, meals and more impact sugar levels
Dexcom on Tuesday announced its first generative AI feature for its Stelo biosensor that gives users a personalized weekly report about their glucose. The company has been building a generative AI platform with technology from Google Cloud.
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DXCM continues to raise optimism among investors owing to its strong product portfolio.
DexCom: Brighter 2025 From Stelo Ramp
DexCom faces challenges in 2024 due to competition and missteps, but the long-term outlook for continuous glucose monitors remains strong. Q3 revenue grew only 2% y/y to $994.2 million, with temporary and long-lasting headwinds impacting growth and margins. The new over-the-counter Stelo CGM launched in August, offering a new growth vector and targeting non-insulin users, with significant ramp-up expected in 2025.
3 Reasons to Buy DexCom Stock Like There's No Tomorrow
Medical device specialist DexCom (DXCM -0.14%) is going through a rough patch. The company's shares are down sharply year to date due to unimpressive financial results -- and some of the headwinds it has encountered are, no doubt, concerning.
2 Excellent Healthcare Stocks to Hold Through the Next Decade
Although excellent medical care is always in high demand, the healthcare sector continuously evolves. Companies aren't automatically worth investing in just because they provide essential medical services.
Why DexCom (DXCM) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
2 Superior Growth Stocks to Buy Right Now If You have $1,000 to Invest
It's not always easy to be a long-term investor, particularly when contending with the natural cyclicality that the stock market presents if you buy and hold through bull as well as bear markets.
